Document is current
Any future updates will be listed below
-
Authors
Gutmann, Clemens https://orcid.org/0000-0003-0675-8632
Takov, Kaloyan https://orcid.org/0000-0002-8642-6306
Burnap, Sean A. https://orcid.org/0000-0002-3408-8608
Singh, Bhawana https://orcid.org/0000-0002-5834-8320
Ali, Hashim
Theofilatos, Konstantinos https://orcid.org/0000-0001-6799-0553
Reed, Ella
Hasman, Maria
Nabeebaccus, Adam
Fish, Matthew https://orcid.org/0000-0001-6462-3889
McPhail, Mark JW.
O’Gallagher, Kevin
Schmidt, Lukas E. https://orcid.org/0000-0001-7565-1455
Cassel, Christian
Rienks, Marieke https://orcid.org/0000-0002-0590-9518
Yin, Xiaoke https://orcid.org/0000-0002-5172-0935
Auzinger, Georg
Napoli, Salvatore
Mujib, Salma F.
Trovato, Francesca
Sanderson, Barnaby https://orcid.org/0000-0002-9621-143X
Merrick, Blair https://orcid.org/0000-0002-6061-6064
Niazi, Umar https://orcid.org/0000-0001-7176-8883
Saqi, Mansoor
Dimitrakopoulou, Konstantina
Fernández-Leiro, Rafael https://orcid.org/0000-0002-7941-0357
Braun, Silke https://orcid.org/0000-0002-2558-1521
Kronstein-Wiedemann, Romy
Doores, Katie J. https://orcid.org/0000-0002-5507-1725
Edgeworth, Jonathan D.
Shah, Ajay M.
Bornstein, Stefan R. https://orcid.org/0000-0002-5211-2536
Tonn, Torsten https://orcid.org/0000-0001-9580-2193
Hayday, Adrian C. https://orcid.org/0000-0002-9495-5793
Giacca, Mauro https://orcid.org/0000-0003-2927-7225
Shankar-Hari, Manu https://orcid.org/0000-0002-5338-2538
Mayr, Manuel https://orcid.org/0000-0002-0597-829X
-
Funding
Funding for this research was provided by:
British Heart Foundation (CH/16/3/32406, RG/16/14/32397, CH/1999001/11735, PG/17/48/32956, SP/17/10/33219, RM/17/3/33381))
Fondation Leducq (18CVD02)
- License Information
-
More Information
Article History
Received: 5 November 2020
Accepted: 28 April 2021
First Online: 7 June 2021
Competing interests
: King’s College London has filed and licensed a patent application with regard to using PTX3 as a biomarker in sepsis. King’s College London has filed a patent application on the methods used to detect SARS-CoV-2 Spike protein-induced syncytia as described in this paper. A.C.H. is a board member and equity holder in ImmunoQure, A.G., and Gamma Delta Therapeutics, and is an equity holder in Adaptate Biotherapeutics.
